Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1985 Dec 1;232(2):415–423. doi: 10.1042/bj2320415

The interaction of hydralazine with a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Its use as a radioactive ligand for the enzyme.

M A Barrand, B A Callingham
PMCID: PMC1152895  PMID: 4091799

Abstract

Hydralazine is a potent irreversible inhibitor of the semicarbazide-sensitive amine oxidase (SSAO) found in brown fat. Initially it may act on the enzyme as a competitive inhibitor, but irreversible inhibition occurs rapidly in a concentration- and temperature-dependent manner. The presence of primary amines known to be substrates for the enzyme, but not of secondary amines, which are not metabolized by SSAO, diminishes this rate of inactivation, whereas removal of O2 is without effect. The kinetic pattern of inactivation of SSAO by hydralazine is consistent with an active-site-directed site-saturable binding followed by the development of an irreversible enzyme-inhibitor complex. [3H]Hydralazine, used as an affinity label for SSAO, shows saturable binding to brown-fat membranes. This binding is inhibited by other inhibitors of SSAO. The rate of binding to membrane pellets containing SSAO is not affected by substrates for the enzyme. However, if solubilized partially purified SSAO preparations are used instead, the rate of binding is lowered in the presence of the SSAO substrate benzylamine. 3H-labelled material solubilized from [3H]hydralazine-treated membrane pellets by Triton X-100 at that detergent/protein ratio which releases SSAO from membranes shows the same gel-filtration characteristics as SSAO and appears by lentil lectin-agarose affinity chromatography to contain similar carbohydrate moieties. 3H-labelled material, partially purified by gel filtration and affinity chromatography, produces predominantly a single band of radioactivity on sodium dodecyl sulphate/polyacrylamide-gel electrophoresis. The position of this band corresponds to an Mr of about 94 000, almost exactly half the Mr already estimated for the functional unit of SSAO. Radiolabelled hydralazine may thus be used as a label for purified SSAO, but it is not specific enough to be suitable as a ligand in vivo.

Full text

PDF
415

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker J. R., Bullock G. R., Williamson I. H. Autoradiographic study of the distribution of [3H]- and [14C]-hydrallazine in the rat. Br J Pharmacol. 1985 Jan;84(1):107–120. [PMC free article] [PubMed] [Google Scholar]
  2. Barker R., Boden N., Cayley G., Charlton S. C., Henson R., Holmes M. C., Kelly I. D., Knowles P. F. Properties of cupric ions in benzylamine oxidase from pig plasma as studied by magnetic-resonance and kinetic methods. Biochem J. 1979 Jan 1;177(1):289–302. doi: 10.1042/bj1770289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barrand M. A., Callingham B. A. Monoamine oxidase activities in brown adipose tissue of the rat: some properties and subcellular distribution. Biochem Pharmacol. 1982 Jun 15;31(12):2177–2184. doi: 10.1016/0006-2952(82)90511-1. [DOI] [PubMed] [Google Scholar]
  4. Barrand M. A., Callingham B. A. Solubilization and some properties of a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Biochem J. 1984 Sep 1;222(2):467–475. doi: 10.1042/bj2220467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barrand M. A., Fox S. A. Amine oxidase activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (clorgyline-resistant) activity at the fat cell membrane. J Pharm Pharmacol. 1984 Oct;36(10):652–658. doi: 10.1111/j.2042-7158.1984.tb04837.x. [DOI] [PubMed] [Google Scholar]
  6. Bhatnagar R. S., Rapaka S. S., Liu T. Z., Wolfe S. M. Hydralazine-induced disturbances in collagen biosynthesis. Biochim Biophys Acta. 1972 Jun 22;271(1):125–132. doi: 10.1016/0005-2795(72)90140-7. [DOI] [PubMed] [Google Scholar]
  7. Callingham B. A., Laverty R. Studies on the nature of the increased monoamine oxidase activity in the rat heart after adrenalectomy. J Pharm Pharmacol. 1973 Dec;25(12):940–947. doi: 10.1111/j.2042-7158.1973.tb09983.x. [DOI] [PubMed] [Google Scholar]
  8. Clarke D. E., Lyles G. A., Callingham B. A. A comparison of cardiac and vascular clorgyline-resistant amine oxidase and monoamine oxidase. Inhibition by amphetamine, mexiletine and other drugs. Biochem Pharmacol. 1982 Jan 1;31(1):27–35. doi: 10.1016/0006-2952(82)90231-3. [DOI] [PubMed] [Google Scholar]
  9. Coquil J. F., Goridis C., Mack G., Neff N. H. Monoamine oxidase in rat arteries: evidence for different forms and selective localization. Br J Pharmacol. 1973 Aug;48(4):590–599. doi: 10.1111/j.1476-5381.1973.tb08245.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Falk M. C., Staton A. J., Williams T. J. Heterogeneity of pig plasma amine oxidase: molecular and catalytic properties of chromatographically isolated forms. Biochemistry. 1983 Aug 2;22(16):3746–3751. doi: 10.1021/bi00285a005. [DOI] [PubMed] [Google Scholar]
  11. Falk M. C. Stoichiometry of phenylhydrazine inactivation of pig plasma amine oxidase. Biochemistry. 1983 Aug 2;22(16):3740–3745. doi: 10.1021/bi00285a004. [DOI] [PubMed] [Google Scholar]
  12. Fuentes J. A., Neff N. H. Inhibition by pargyline of cardiovascular amine oxidase activity. Biochem Pharmacol. 1977 Nov 15;26(22):2107–2112. doi: 10.1016/0006-2952(77)90259-3. [DOI] [PubMed] [Google Scholar]
  13. Inamasu M., Yasunobu K. T. Cofactor investigation of bovine plasma amine oxidase. NaBH4 reduction of enzyme-substrate mixture. J Biol Chem. 1974 Aug 25;249(16):5265–5268. [PubMed] [Google Scholar]
  14. Kreye V. A., Schlicker E. Effects of vasodilator drugs, alkaline phosphatase, and cyclic AMP-dependent protein kinase on the 45calcium uptake of sarcolemmal microsomes from human umbilical arteries. Br J Pharmacol. 1980 Dec;70(4):537–544. doi: 10.1111/j.1476-5381.1980.tb09772.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kwan C. Y., Daniel E. E. Arterial muscle membrane abnormalities of hydralazine-treated spontaneously hypertensive rats. Eur J Pharmacol. 1982 Aug 27;82(3-4):187–190. doi: 10.1016/0014-2999(82)90510-6. [DOI] [PubMed] [Google Scholar]
  16. Köchli H., Von Wartburg J. P. A sensitive photometric assay for monoamine oxidase. Anal Biochem. 1978 Jan;84(1):127–135. doi: 10.1016/0003-2697(78)90491-8. [DOI] [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Lewinsohn R. Amine oxidase in human blood vessels and non-vascular smooth muscle. J Pharm Pharmacol. 1981 Sep;33(9):569–575. doi: 10.1111/j.2042-7158.1981.tb13868.x. [DOI] [PubMed] [Google Scholar]
  19. Lindström A., Olsson B., Pettersson G. Kinetics of the interaction between pig-plasma benzylamine oxidase and hydrazine derivatives. Eur J Biochem. 1974 Feb 15;42(1):177–182. doi: 10.1111/j.1432-1033.1974.tb03327.x. [DOI] [PubMed] [Google Scholar]
  20. Lindström A., Pettersson G. Active-site titration of pig-plasma benzylamine oxidase. Eur J Biochem. 1978 Feb 1;83(1):131–135. doi: 10.1111/j.1432-1033.1978.tb12076.x. [DOI] [PubMed] [Google Scholar]
  21. Lipe S., Moulds R. F. In vitro differences between human arteries and veins in their responses to hydralazine. J Pharmacol Exp Ther. 1981 Apr;217(1):204–208. [PubMed] [Google Scholar]
  22. Liu T. Z., Shen J. T., Loken H. F. Inhibition of dopamine-beta-hydroxylase by hydralazine. Proc Soc Exp Biol Med. 1974 Jan;145(1):294–297. doi: 10.3181/00379727-145-37796. [DOI] [PubMed] [Google Scholar]
  23. Lyles G. A., Callingham B. A. Hydralazine is an irreversible inhibitor of the semicarbazide-sensitive, clorgyline-resistant amine oxidase in rat aorta homogenates. J Pharm Pharmacol. 1982 Feb;34(2):139–140. doi: 10.1111/j.2042-7158.1982.tb04209.x. [DOI] [PubMed] [Google Scholar]
  24. Lyles G. A., Garcia-Rodriguez J., Callingham B. A. Inhibitory actions of hydralazine upon monoamine oxidizing enzymes in the rat. Biochem Pharmacol. 1983 Sep 1;32(17):2515–2521. doi: 10.1016/0006-2952(83)90012-6. [DOI] [PubMed] [Google Scholar]
  25. Maekawa K., Liang C. S., Tsui A., Chen B. T., Kawashima S. Vasodilative effect of hydralazine in awake dogs: the roles of prostaglandins and the sympathetic nervous system. Circulation. 1984 Nov;70(5):908–916. doi: 10.1161/01.cir.70.5.908. [DOI] [PubMed] [Google Scholar]
  26. Massey J. B., Churchich J. E. Kynuramine, a fluorescent substrate and probe of plasma amine oxidase. J Biol Chem. 1977 Nov 25;252(22):8081–8084. [PubMed] [Google Scholar]
  27. McLean A. J., du Souich P., Barron K. W., Briggs A. H. Interaction of hydralazine with tension development and mechanisms of calcium accumulation in K+-stimulated rabbit aortic strips. J Pharmacol Exp Ther. 1978 Oct;207(1):40–48. [PubMed] [Google Scholar]
  28. Numata Y., Takei T., Hayakawa T. Hydralazine as an inhibitor of lysyl oxidase activity. Biochem Pharmacol. 1981 Nov 15;30(22):3125–3126. doi: 10.1016/0006-2952(81)90505-0. [DOI] [PubMed] [Google Scholar]
  29. Peers E. M., Lyles G. A., Callingham B. A. The deamination of isoamylamine by monamine oxidase in mitochondrial preparations from rat liver and heart: a comparison with phenylethylamine. Biochem Pharmacol. 1980 Apr 15;29(8):1097–1102. doi: 10.1016/0006-2952(80)90402-5. [DOI] [PubMed] [Google Scholar]
  30. Rando R. R. Mechanism-based enzyme inactivators. Pharmacol Rev. 1984 Jun;36(2):111–142. [PubMed] [Google Scholar]
  31. Sinha B. K., Patterson M. A. Free radical metabolism of hydralazine. Binding and degradation of nucleic acids. Biochem Pharmacol. 1983 Nov 15;32(22):3279–3284. doi: 10.1016/0006-2952(83)90351-9. [DOI] [PubMed] [Google Scholar]
  32. Udenfriend S., Stein S., Böhlen P., Dairman W., Leimgruber W., Weigele M. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science. 1972 Nov 24;178(4063):871–872. doi: 10.1126/science.178.4063.871. [DOI] [PubMed] [Google Scholar]
  33. Waley S. G. Kinetics of suicide substrates. Biochem J. 1980 Mar 1;185(3):771–773. doi: 10.1042/bj1850771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wibo M., Duong A. T., Godfraind T. Subcellular location of semicarbazide-sensitive amine oxidase in rat aorta. Eur J Biochem. 1980 Nov;112(1):87–94. doi: 10.1111/j.1432-1033.1980.tb04990.x. [DOI] [PubMed] [Google Scholar]
  35. Yasunobu K. T., Ishizaki H., Minamiura N. The molecular mechanistic and immunological properties of amine oxidases. Mol Cell Biochem. 1976 Oct 30;13(1):3–29. doi: 10.1007/BF01732392. [DOI] [PubMed] [Google Scholar]
  36. del Carmen Urdin M., Fuentes J. A. Enzyme activity of an amine oxidase to pargyline in the cardiovascular system of hypertensive rats. Biochem Pharmacol. 1983 Aug 1;32(15):2345–2347. doi: 10.1016/0006-2952(83)90184-3. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES